Regulatory Approvals

FDA clears Roche’s Enspryng for thyroid eye disease

By

Regulatory Approvals — FDA clears Roche's Enspryng for thyroid eye disease  pharmaphorum

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. October 16, 2026.

By

Related Post

Regulatory Approvals

FDA clears Roche’s Enspryng as first at-home therapy for thyroid eye disease

Regulatory Approvals

GE HealthCare secures CE mark for MINItrace Magni cyclotron

Regulatory Approvals

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

Financial News For All

Regulation

EPA completes cleanup of former hospital site in Colorado

Regulation

EPA Regional Administrators Visit Farms in Maryland and Kentucky to Highlight Soil Health, Water Quality, and Agricultural Partnership

Business Economy Finance

Commodities Price Update: Crude Oil $96.51, Brent $106.54, Copper $6.64, Coal $104.75 — Oct 16, 2026 8:00 AM EDT

Mergers & Acquisitions

Elon Musk Could Announce A Tesla-SpaceX Merger In Coming Weeks: Analyst